Erythropoietin reduces ischemia-reperfusion injury in the rat liver

European Surgical Research

Volumn 39, Issue 3, 2007, Pages 189-197

  Schmeding, M ^a   Neumann, U P ^a   Boas Knoop, S ^a   Spinelli, A ^a   Neuhaus, P ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Erythropoietin; Ischemia reperfusion injury; Warm hepatic ischemia

Indexed keywords

BETA ACTIN; ERYTHROPOIETIN; LIVER ENZYME; MESSENGER RNA; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ANALYSIS; LIVER; LIVER INJURY; LIVER ISCHEMIA; LIVER TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; STATISTICAL SIGNIFICANCE; UPREGULATION;

ANIMALS; ERYTHROPOIETIN; IN SITU NICK-END LABELING; ISCHEMIC PRECONDITIONING; LIVER; MALE; RATS; RATS, WISTAR; REPERFUSION INJURY; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247329767     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000101009     Document Type: Article

References (35)

1. Grasso G: Neuroprotective effect of recombinant human erythropoietin in experimental subarachnoid hemorrhage. J Neurosurg Sci 2001;45:7-14.
2. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, et al: Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003;100:4802-4806.
3. Gassmann M, Heinicke K, Soliz J, Ogunshola OO, Marti HH, Hofer T, Grimm C, et al: Non-erythroid functions of erythropoietin. Adv Exp Med Biol 2003;543:323-330.
4. Kumral A, Ozer E, Yilmaz O, Akhisaroglu M, Gokmen N, Duman N, Ulukus C, et al: Neuroprotective effect of erythropoietin on hypoxic-ischemic brain injury in neonatal rats. Biol Neonate 2003;83:224-228.
5. Abdelrahman M, Sharples EJ, McDonald MC, Collin M, Patel NS, Yaqoob MM, Thiemermann C: Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 2004;22:63-69.
6. Bullard AJ, Govewalla P, Yellon DM: Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 2005;100:397-403.
7. Fisher JW: Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 2003;228:1-14.
8. Kretz A, Happold CJ, Marticke JK, Isenmann S: Erythropoietin promotes regeneration of adult CNS neurons via Jak-2/STAT-3 and PI3K/AKT pathway activation. Mol Cell Neurosci 2005;29:569-579.
9. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, et al: A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112:999-1007.
10. Xuan YT, Guo Y, Han H, Zhu Y, Bolli R: An essential role of the Jak-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci USA 2001;98:9050-9055.
11. Marti HH: Erythropoietin and the hypoxic brain. J Exp Biol 2004;207:3233-3242.
12. 2-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1. J Appl Physiol 2004;96:1170-1177.
13. Wang X, Zhu C, Gerwien JG, Schrattenholz A, Sandberg M, Leist M, Blomgren K: The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin. J Neurochem 2004;91:900-910.
14. Ehrenreich H, Timner W, Siren AL: A novel role for an established player: anemia drug erythropoietin for the treatment of cerebral hypoxia/ischemia. Transfus Apheresis Sci 2004;31:39-44.
15. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW: Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 2004;19:348-355.
16. Sepodes B, Maio R, Pinto R, Sharples E, Oliveira P, McDonald M, Yaqoob M, et al: Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl Int 2006;19:919-926.
17. Compagnon P, Lindell S, Ametani MS, Gilligan B, Wang HB, D'Alessandro AM, Southard JH, et al: Ischemic preconditioning and liver tolerance to warm or cold ischemia: experimental studies in large animals. Transplantation 2005;79:1393-1400.
18. Teoh NC, Farrell GC: Hepatic ischemia-reperfusion injury: pathogenic mechanisms and basis for hepatoprotection. J Gastroenterol Hepatol 2003;18:891-902.
19. Guo L, Haga S, Enosawa S, Naruse K, Harihara Y, Sugawara Y, Irani K, et al: Improved hepatic regeneration with reduced injury by redox factor-1 in a rat small-sized liver transplant model. Am J Transplant 2004;4:879-887.
20. Hasselgren PO: Prevention and treatment of ischemia of the liver. Surg Gynecol Obstet 1987;164:187-196.
21. Sileri P, Schena S, Fukada J, Rastellini C, Pirenne J, Benedetti E, Cicalese L: Corticosteroids enhance hepatic injury following ischemia-reperfusion. Transplant Proc 2001;33:3712.
22. Chouker A, Schachtner T, Schauer R, Dugas M, Lohe F, Martignoni A, Pollwein B, et al: Effects of Pringle manoeuvre and ischaemic preconditioning on haemodynamic stability in patients undergoing elective hepatectomy: a randomized trial. Br J Anaesth 2004;93:204-211.
23. Maiese K, Li F, Chong ZZ: New avenues of exploration for erythropoietin. JAMA 2005;293:90-95.
24. Ruscher K, Freyer D, Karsch M, Isaev N, Megow D, Sawitzki B, Priller J, et al: Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 2002;22:10291-10301.
25. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S, Rosenbaum PS, et al: Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 2002;99:10659-10664.
26. Stephanou A: Activated STAT-1 pathway in the myocardium as a novel therapeutic target in ischaemia/reperfusion injury. Eur Cytokine Netw 2002;13:401-403.
27. Haga S, Terui K, Zhang HQ, Enosawa S, Ogawa W, Inoue H, Okuyama T, et al: STAT-3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J Clin Invest 2003;112:989-998.
28. Bittorf T, Jaster R, Ludtke B, Kamper B, Brock J: Requirement for Jak-2 in erythropoietin-induced signalling pathways. Cell Signal 1997;9:85-89.
29. Watowich SS, Mikami A, Busche RA, Xie X, Pharr PN, Longmore GD: Erythropoietin receptors that signal through STAT-5 or STAT-3 support fetal liver and adult erythropoiesis: lack of specificity of STAT signals during red blood cell development. J Interferon Cytokine Res 2000;20:1065-1070.
30. Lipsic E, van der Meer P, Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen DJ, van Gilst WH, et al: Timing of erythropoietin treatment for cardioprotection in ischemia/ reperfusion. J Cardiovasc Pharmacol 2004;44:473-479.
31. Patel NS, Sharples EJ, Cuzzocrea S, Chatterjee PK, Britti D, Yaqoob MM, Thiemermann C: Pretreatment with Epo reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int 2004;66:983-989.
32. Fan H, Kanji S, Zhai M: Proliferative signal transmission mediated by EpoR in leukemic cell lines. Zhonghua Xue Ye Xue Za Zhi 2000;21:294-297.
33. Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N: Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001;98:5181-5186.
34. Sigounas G, Sallah S, Sigounas VY: Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model. Cancer Lett 2004;214:171-179.
35. Ferrario E, Ferrari L, Bidoli P, De Candis D, Del Vecchio M, De Dosso S, Buzzoni R, et al: Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat Rev 2004;30:563-575.